Cargando…

Cardiovascular Risk Factor Reduction in First Responders Resulting From an Individualized Lifestyle and Blood Test Program: A Randomized Controlled Trial

OBJECTIVE: We tested the hypothesis that a lifestyle program would improve risk factors linked to cardiovascular disease (CVD) in first responders. METHODS: A 1-year cluster-randomized controlled clinical trial in 10 cities. Participants were 175 first responders, with increased waist circumference...

Descripción completa

Detalles Bibliográficos
Autores principales: Gill, Rosalynn, Superko, Harold Robert, McCarthy, Megan M., Jack, Kepra, Jones, Briana, Ghosh, Debanjali, Richards, Steve, Gleason, Joi A., Williams, Paul T., Dansinger, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416033/
https://www.ncbi.nlm.nih.gov/pubmed/30475306
http://dx.doi.org/10.1097/JOM.0000000000001490
Descripción
Sumario:OBJECTIVE: We tested the hypothesis that a lifestyle program would improve risk factors linked to cardiovascular disease (CVD) in first responders. METHODS: A 1-year cluster-randomized controlled clinical trial in 10 cities. Participants were 175 first responders, with increased waist circumference and/or low levels of large (α(1)) high-density lipoprotein (HDL) particles. The intervention group received personalized online tools and access to telephonic coaching sessions. RESULTS: At 1 year the intervention significantly reduced body weight (P = 0.004) and waist circumference (P = 0.002), increased α(1) HDL (P = 0.01), and decreased triglyceride (P = 0.005) and insulin concentrations (P = 0.03). Program adherence was associated with weight loss (P = 0.0005) and increases in α(1) HDL (P = 0.03). CONCLUSIONS: In first responders, a personalized lifestyle intervention significantly improved CVD risk factors in proportion to program adherence. Changes in large HDL particles were more sensitive indicators of lifestyle changes than HDL-cholesterol measurement. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT03322046